


Two delivery platforms
We 3D-print medicines at room temperature, with no heat and no UV, on two delivery platforms. Our initial pipeline is peptides, which usually must be injected: under 1% of a swallowed dose is absorbed. Since October 2026, HHS lets 503A pharmacies compound six peptides; only KPV and BPC-157 are covered for oral use.

Colon-targeted
The patent-pending pill-in-pill holds through the stomach and releases its dose in the colon, where gut disease is.

Mucoadhesive Oral films
A printed mucoadhesive film sticks to the inside of the cheek. The dose passes through the cheek lining into the bloodstream, bypassing the gut and first-pass liver metabolism.
Initial pipeline: BPC-157 and KPV
Both peptides are being developed on both platforms.
Explore our peptide pipelineCompounded products are patient-specific prescriptions and are not FDA-approved. No efficacy claims are made. The oral film is in development and its regulatory pathway has not been established. Images are renders.

